Home › Research › Down syndrome and Alzheimer's
Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts
Jr‐Jiun Liou, Tales Santini, Miloš D. Ikonomović, Victor L. Villemagne, Ann D. Cohen, Charles M. Laymon, Davneet Singh Minhas, Weiquan Luo et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
The ABC-DS cohort showed similar Aβ PET burden but had a lower prevalence of ApoE4 carriers, younger age at clinical diagnosis and autopsy, shorter PET-autopsy interval, smaller amygdala and hippocampal volumes, more advanced CERAD scores, and no atherosclerosis compared to ADRC cohort (Figure 1). In our existing datasets, the association between age at PET scan and Aβ burden did not reach statistical significance likely due to limited sample size. Antemortem Aβ burden was not associated with postmortem amygdala or hippocampal volumes in either group (Figure 2). Higher Aβ burden was associated with advanced LATE-NC stage in ABC-DS but not in ADRC. In ADRC, Aβ burden correlated with postmortem Aβ plaque, neurofibrillary tangles, and neuritic plaques, while no significant associations were found in ABC-DS for Thal phase, Braak NFT stage, or CERAD score (Figure 3). In DS, antemortem Aβ PET burden is associated with advanced LATE-NC stage but not with postmortem amygdala or hippocampal volumes. In ADRC cohort, Aβ burden correlates with postmortem amyloid plaque, neurofibrillary tangle, and neuritic plaque pathology.
Key findings
- The ABC-DS cohort showed similar Aβ PET burden but had a lower prevalence of ApoE4 carriers, younger age at clinical diagnosis and autopsy, shorter PET-autopsy interval, smaller amygdala and hippocampal volumes, more advanced CERAD scores, and no atherosclerosis compared to ADRC cohort (Figure 1).
- In our existing datasets, the association between age at PET scan and Aβ burden did not reach statistical significance likely due to limited sample size.
- Antemortem Aβ burden was not associated with postmortem amygdala or hippocampal volumes in either group (Figure 2).
- Higher Aβ burden was associated with advanced LATE-NC stage in ABC-DS but not in ADRC.
- In ADRC, Aβ burden correlated with postmortem Aβ plaque, neurofibrillary tangles, and neuritic plaques, while no significant associations were found in ABC-DS for Thal phase, Braak NFT stage, or CERAD score (Figure 3).
Why it matters
In the Down syndrome cohort, antemortem amyloid PET burden was associated with advanced LATE-NC stage but not with postmortem amygdala or hippocampal volumes, and no significant associations were found for Thal phase, Braak NFT stage or CERAD score. These correlational autopsy findings do not show how to treat, cure or prevent Alzheimer's disease.
Study details
- Evidence strengthModerate
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Tamer S. Ibrahim: h-index 8 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41453185) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_103737
- PubMed: 41453185
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Liou, J., Santini, T., Ikonomović, M. D., Villemagne, V. L., Cohen, A. D., Laymon, C. M., et al. (2025). Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_103737
Vancouver
Liou J, Santini T, Ikonomović MD, Villemagne VL, Cohen AD, Laymon CM, et al. Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_103737. PMID: 41453185.
BibTeX
@article{liou2025-41453185,
author = {Liou, Jr‐Jiun and Santini, Tales and Ikonomović, Miloš D. and Villemagne, Victor L. and Cohen, Ann D. and Laymon, Charles M. and Minhas, Davneet Singh and Luo, Weiquan and others},
title = {{Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_103737},
pmid = {41453185},
url = {https://doi.org/10.1002/alz70856_103737}
}
Related studies in Down syndrome and Alzheimer's
Also tagged “classification”
835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.